NAFLD vs MASLD: What the Name Change Means for Indian Patients | ALIV

If you were diagnosed with "NAFLD" a few years ago and have recently seen "MASLD" in medical literature or on a new report, you might reasonably wonder whether you have a different condition — or whether your old diagnosis still applies. You have the same condition. The name changed. And understanding why the name changed matters for how you think about your diagnosis and your treatment approach.

What NAFLD Was and Why It Was Renamed

NAFLD — Non-Alcoholic Fatty Liver Disease — was defined by exclusion: fatty liver that was not caused by significant alcohol consumption. The problem with a name defined by what a condition is not is that it tells you nothing about what it is. It provides no information about the driving mechanism, no guidance on treatment direction, and no insight into why this particular person developed fatty liver when a neighbour with the same alcohol intake did not.

In 2023, a major international consensus — involving hepatologists, endocrinologists, and patient advocates — renamed the condition MASLD: Metabolic dysfunction-Associated Steatotic Liver Disease. The renaming reflects what research has consistently shown: fatty liver in the vast majority of patients is driven by metabolic dysfunction — specifically insulin resistance, excess visceral adiposity, and related metabolic abnormalities — not simply by the absence of alcohol. The new name is defined by what the condition is, not what it is not. This is a meaningful clinical improvement in diagnostic language.

What MASLD Requires for Diagnosis

The new MASLD classification requires both: evidence of hepatic steatosis (fat in the liver, typically detected by ultrasound or other imaging) AND at least one of five cardiometabolic risk factors: overweight or obesity (BMI ≥25 in Western populations, ≥23 in Asian populations including Indians), prediabetes or type 2 diabetes, elevated fasting glucose or HbA1c, elevated blood pressure (≥130/85 mmHg or on antihypertensives), or dyslipidaemia (elevated triglycerides or low HDL). For Indian patients, virtually all patients with fatty liver will meet at least one of these criteria — making the transition from NAFLD to MASLD diagnostically inclusive rather than exclusive for this population. Read our complete liver health guide: liver health and fatty liver in India.

Why This Name Change Matters for Treatment

The most clinically important implication of the MASLD renaming: it explicitly frames fatty liver as a metabolic condition requiring metabolic treatment. Not just "avoid fatty foods" and "reduce alcohol" — but address insulin resistance, manage visceral fat accumulation, optimise carbohydrate quality, and treat the underlying cardiometabolic drivers. This is the treatment framework that actually produces results — and it is the framework ALIV's clinical team in Pune and Mumbai has applied to liver health long before the official name change formalised it. For the connection between fatty liver and metabolic health, read: fatty liver and belly fat — the connected drivers.

Does the name change affect my diagnosis or treatment?

Not directly — if you were diagnosed with NAFLD and that diagnosis was correct, you now have MASLD. Your condition has not changed. The treatment approach has not changed either — but the new name should prompt a more explicit metabolic assessment from your treating physician, including evaluation of insulin resistance, visceral fat, and cardiometabolic risk factors that might have been underemphasised under the NAFLD framing.

What is the difference between MASLD, MASH, and cirrhosis?

MASLD is the umbrella diagnosis — fat in the liver with metabolic dysfunction. MASH (Metabolic dysfunction-Associated Steatohepatitis, formerly NASH) is MASLD with significant liver cell inflammation and beginning fibrosis — a more advanced stage. Cirrhosis is the end-stage of liver fibrosis — extensive scarring that impairs liver function. Most patients with MASLD have the earlier, more reversible stage; only a minority progress to MASH and fewer still to cirrhosis. Read: fatty liver grades 1, 2, and 3 explained.

Can MASLD be detected on a standard blood test?

Not definitively — elevated liver enzymes (ALT, AST) suggest liver stress but do not confirm MASLD. Most patients with early MASLD have normal liver enzymes. Diagnosis requires imaging — liver ultrasound being the most accessible first-line tool. More precise quantification uses fibroscan (liver elastography) or MRI-based fat assessment. See: how to interpret a liver ultrasound report.

Is MASLD reversible?

Yes — particularly in the early stages (Grade 1 and 2 hepatic steatosis). The liver is one of the few organs with significant regenerative capacity. With sustained dietary change, weight reduction where relevant, and management of the underlying metabolic drivers, liver fat reduction is well-documented in clinical studies. The timeline for meaningful reversal varies by the severity of the condition and the consistency of the intervention — typically six months to two years for significant improvement. Read: can lifestyle reverse fatty liver.

Is MASLD the same as alcoholic fatty liver disease?

No. The new classification system separates them explicitly. MetALD is the new term for patients who have both metabolic dysfunction-associated liver changes and significant alcohol consumption. Alcoholic liver disease (ALD) refers to liver damage primarily driven by alcohol without the metabolic dysfunction picture. The therapeutic approaches differ — MASLD is primarily addressed through metabolic interventions; alcohol-related disease requires alcohol cessation as the primary intervention. ALIV's Alcohol Liver Reset is designed specifically for alcohol-related hepatic support.